Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1R
Clinical data
ATC code none
CAS Number 905703-97-1 N
ChemSpider none
Chemical and physical data
Formula C6472H10028N1728O2020S42
Molar mass 145.7 kg/mol
 NYesY (what is this?)  (verify)

Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[2][3]


  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
  2. "Amgen Pulls Cancer Drug". 10 Aug 2012.
  3. "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012.

This article is issued from Wikipedia - version of the 8/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.